The costs of running this huge site are paid for by ads. Please consider registering and becoming a Supporting Member for an ad-free experience. Thanks, ECF team.

The FDA Postpone PMTA Application Deadline to 2022

Discussion in 'Heaven Gifts' started by AlmightyEvan, Jul 31, 2017.

Image has been removed.
URL has been removed.
Email address has been removed.
Media has been removed.
  1. AlmightyEvan

    AlmightyEvan Supplier Associate ECF Veteran

    Jan 25, 2016
    Shanghai, China
    Last year, the proposal for regulating electronic nicotine delivery systems issued by the FDA dropped a bomb in the community, making many e-cig vendors and vapers worry about the future of this industry. But now you can breathe a sigh of relief, as the FDA just made a major announcement regarding the delay of PMTA application.

    Under expected revised timelines, applications for non-combustible products such as ENDS or e-cigarettes would be submitted by Aug. 8, 2022. Additionally, the FDA expects that manufacturers would continue to market products while the agency reviews product applications. Importantly, the new enforcement policy is not expected to affect any current requirements for cigarettes and smokeless tobacco, only the newly-regulated tobacco products such as cigars and e-cigarettes. It also will not apply to provisions of the final rule for which compliance deadlines already have passed, such as mandatory age and photo-ID checks at sales counters.

    "To complement these larger policy considerations, the FDA plans to issue foundational rules to make the product review process more efficient, predictable, and transparent for manufacturers, while upholding the agency’s public health mission." From these reassuring words, we can set our hearts at rest. It seems the FDA's harsh attitude towards e-cigarettes start to be softening.
    • Like Like x 4

Share This Page

  1. This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
    By continuing to use this site, you are consenting to our use of cookies.
    Dismiss Notice